You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

trastuzumab

Showing 51 - 75 of 1,505
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ado-trastuzumab Emtansine-Induced Peripheral Neuropathy in

Recruiting
  • Breast Neoplasm
    • Rochester, Minnesota
      Mayo Clinic Minnesota
    Jun 12, 2023

    Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)

    Active, not recruiting
    • Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 10, 2022

    Breast Cancer Trial in Shanghai (Pertuzumab)

    Not yet recruiting
    • Breast Cancer
    • Shanghai, Shanghai, China
      Shanghai Jiaotong University School of Medicine affiliated Ruiji
    Jun 4, 2023

    Metastatic Cancer, HER2 Gene Mutation Trial in Seoul (Neratinib Maleate)

    Active, not recruiting
    • Metastatic Cancer
    • HER2 Gene Mutation
    • Neratinib Maleate
    • Seoul, Korea, Republic of
      Korea university Guro hospital
    Oct 18, 2023

    DESTINY Breast Respond HER2-low Europe

    Not yet recruiting
    • Unresectable Breast Cancer
    • +2 more
    • Trastuzumab deruxtecan
    • (no location specified)
    Jul 6, 2023

    Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in New Haven (procedure, drug, biological)

    Recruiting
    • Metastatic Malignant Solid Neoplasm
    • Unresectable Malignant Solid Neoplasm
    • Biopsy
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Jan 25, 2023

    HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

    Not yet recruiting
    • HER2-PositiveRecurrent or Metastatic Breast Cancer
    • SHR-A1811 Injection
    • +2 more
    • (no location specified)
    Sep 21, 2023

    Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)

    Not yet recruiting
    • Brain Metastases
    • HER2-positive Breast Cancer
    • Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
    • (no location specified)
    Jan 10, 2023

    Breast Cancer Trial in Houston (Trastuzumab deruxtecan, Valemetostat)

    Not yet recruiting
    • Breast Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 14, 2022

    HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)

    Recruiting
    • HER2-positive Breast Cancer
    • Dendritic Cell (DC1) Vaccine
    • +3 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    Breast Cancer Trial in Shenyang (Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole)

    Recruiting
    • Breast Cancer
    • Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole
    • Shenyang, Liaoning, China
      Shengjing Hospital of China Medical University
    Sep 12, 2022

    Breast Cancer Metastatic, Leptomeningeal Metastasis Trial (Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection)

    Not yet recruiting
    • Breast Cancer Metastatic
    • Leptomeningeal Metastasis
    • Tucatinib Oral Tablet
    • +2 more
    • (no location specified)
    Mar 23, 2023

    Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

    Recruiting
    • Breast Cancer
    • Pegylated liposomal doxorubicin
    • +5 more
    • Shanghai, China
      Shanghai Pudong Hospital
    Dec 11, 2022

    Breast Cancer Trial in Amsterdam (Monalizumab, Trastuzumab)

    Active, not recruiting
    • Breast Cancer
    • Monalizumab
    • Trastuzumab
    • Amsterdam, Netherlands
      NKI-AVL
    Jul 15, 2022

    Esophagogastric Adenocarcinoma Trial (Pembrolizumab, Trastuzumab, FLOT)

    Not yet recruiting
    • Esophagogastric Adenocarcinoma
    • (no location specified)
    Aug 17, 2022

    HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

    Not yet recruiting
    • HER2-positive Breast Cancer
    • trastuzumab deruxtecan (T-DXd) (IV)
    • Galway, Connaught, Ireland
    • +4 more
    Jan 24, 2023

    Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

    Recruiting
    • Metastatic Breast Cancer
    • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
    • Rome, Italy
      Fondazione Policlinico A. Gemelli - IRCCS
    Jun 22, 2023

    Breast Cancer Trial in Nanjing (Pyrotinib, trastuzumab, abraxane)

    Not yet recruiting
    • Breast Cancer
    • Pyrotinib, trastuzumab, abraxane
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Dec 20, 2022

    Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Spain (Trastuzumab deruxtecan)

    Not yet recruiting
    • Locally Advanced Breast Cancer
    • Metastatic Breast Cancer
    • Trastuzumab deruxtecan
    • Cádiz, Andalucía, Spain
    • +18 more
    Feb 24, 2023

    HER2-positive Breast Cancer Trial (Paclitaxel + Trastuzumab, Trastuzumab)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Paclitaxel + Trastuzumab
    • Trastuzumab
    • (no location specified)
    May 24, 2022

    Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

    Recruiting
    • Brain Metastases
    • +2 more
    • Trastuzumab
    • +3 more
    • Saint Louis, Missouri
    • +1 more
    Nov 8, 2022

    Healthy Male Subjects Trial in Auckland, Christchurch (Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC),

    Recruiting
    • Healthy Male Subjects
    • Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
    • +2 more
    • Adelaide, South Australia, Australia
    • +3 more
    Feb 1, 2023

    Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

    Not yet recruiting
    • Triple-Negative Breast Cancer
    • Trastuzumab Deruxtecan
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jul 12, 2023

    Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab

    Not yet recruiting
    • Invasive Breast Cancer
    • +4 more
    • Boston, Massachusetts
    • +1 more
    Mar 20, 2023

    HER2-positive Breast Cancer, Metastatic Breast Cancer Trial in Shanghai (Trastuzumab plus chemo, Trastuzumab in combination with

    Recruiting
    • HER2-positive Breast Cancer
    • Metastatic Breast Cancer
    • Trastuzumab plus chemotherapy
    • Trastuzumab in combination with pyrotinib plus chemotherapy
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2022